{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:45:16Z","timestamp":1792496716464,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharmacy Therapeu"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1111\/jcpt.13574","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T02:54:27Z","timestamp":1640746467000},"page":"184-193","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clinical review of subcutaneous semaglutide for obesity"],"prefix":"10.1155","volume":"47","author":[{"given":"Anna","family":"Phillips","sequence":"first","affiliation":[{"name":"Presbyterian College School of Pharmacy  Clinton South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-6651","authenticated-orcid":false,"given":"Jennifer N.","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Nursing Administration Spartanburg Regional Healthcare System  Spartanburg South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"BaysHE McCarthyW BurridgeK et al.Obesity Algorithm eBook presented by the Obesity Medicine Association.www.obesityalgorithm.org.2021.https:\/\/obesitymedicine.org\/obesity\u2010algorithm"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614362"},{"key":"e_1_2_6_4_1","unstructured":"Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion Division of Nutrition Physical Activity and Obesity.Data Trend and Maps [online]. Accessed May 23 2021.https:\/\/www.cdc.gov\/nccdphp\/dnpao\/data\u2010trends\u2010maps\/index.html"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2020.07.002"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1909301"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3415"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.004"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150990"},{"issue":"2","key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/dc15-0165","article-title":"A phase 2, randomized, dose\u2010finding study of the novel once\u2010weekly human GLP\u20101 analog, semaglutide, compared with placebo and open\u2010label liraglutide in patients With type 2 diabetes","volume":"39","author":"Nauck MA","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0528-2"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1131"},{"key":"e_1_2_6_17_1","unstructured":"Food and Drug Administration.Guidance for industry: Developing products for weight management (draft guidance). Accessed August 1 2021.http:\/\/www.gda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071612.pdf"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_6_22_1","unstructured":"ClinicalTrials.gov [Internet].Bethesda (MD): National Library of Medicine (US). Identifier NCT03693430 Two\u2010year research study investigating how well semaglutide works in people suffering from overweight or obesity (STEP 5). Accessed September 8 2021.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03693430"},{"key":"e_1_2_6_23_1","unstructured":"ClinicalTrials.gov [Internet].Bethesda (MD): National Library of Medicine (US). Identifier NCT03811574 STEP 6: Research study investigating how well semaglutide works in people living with overweight or obesity. Accessed September 8 2021.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03811574"},{"key":"e_1_2_6_24_1","unstructured":"ClinicalTrials.gov [Internet].Bethesda (MD): National Library of Medicine (US). Identifier NCT04251156 Research study of how ell semaglutide works in people living with overweight or obesity (STEP 7). Accessed September 8 2021.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT04251156"},{"key":"e_1_2_6_25_1","unstructured":"ClinicalTrials.gov [Internet].Bethesda (MD): National Library of Medicine (US). Identifier NCT04074161 Research study to investigate how well semaglutide works compared to liraglutide in people living with overweight or obesity (STEP 8). Accessed September 8 2021.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT04074161"},{"key":"e_1_2_6_26_1","unstructured":"ClinicalTrials.gov [Internet].Bethesda (MD): National Library of Medicine (US). Identifier NCT03574597 Semaglutide effects on heart disease and stroke in patients with overweight or obesity (SELECT). Accessed September 8 2021.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03574597"},{"key":"e_1_2_6_27_1","unstructured":"Wegovy (semaglutide) [package insert].Novo Nordisk Inc;2021."}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.13574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jcpt.13574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcpt.13574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:06Z","timestamp":1671818706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.13574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/jcpt.13574"],"URL":"https:\/\/doi.org\/10.1111\/jcpt.13574","archive":["Portico"],"relation":{},"ISSN":["0269-4727","1365-2710"],"issn-type":[{"value":"0269-4727","type":"print"},{"value":"1365-2710","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"2021-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}